Eli Lilly and Co announced the appointment of Lucas Montarce as the new executive vice president and chief financial officer (CFO), effective September 9, 2024. Montarce, who has been with the company since 2001, has held various finance leadership roles, most recently as president and general manager for the Spain, Portugal, and Greece hub. His previous positions include group vice president, controller and CFO of Lilly Research Laboratories, and vice president, finance and global CFO of Elanco Health. Montarce's election follows a comprehensive search across different industries. He will receive an annual base salary of $1 million, with eligibility for an equal target bonus. The company highlighted that there are no familial or transactional conflicts of interest in Montarce's appointment. The announcement was made in a press release attached as Exhibit 99.1 to the Current Report on Form 8-K filed with the SEC.

Eli Lilly and Co announced the appointment of Lucas Montarce as the new executive vice president and chief financial officer (CFO), effective September 9, 2024. Montarce, who has been with the company since 2001, has held various finance leadership roles, most recently as president and general manager for the Spain, Portugal, and Greece hub. His previous positions include group vice president, controller and CFO of Lilly Research Laboratories, and vice president, finance and global CFO of Elanco Health. Montarce's election follows a comprehensive search across different industries. He will receive an annual base salary of $1 million, with eligibility for an equal target bonus. The company highlighted that there are no familial or transactional conflicts of interest in Montarce's appointment. The announcement was made in a press release attached as Exhibit 99.1 to the Current Report on Form 8-K filed with the SEC.